Colin Keating

MindBio Therapeutics Pty Ltd. is a multi-award-winning leader in microdosing psychedelic medicines. The company is based in Melbourne, Australia, and has subsidiaries in Australia. MindBio Therapeutics is focused on creating treatments for mental health conditions, and its clinical trials focusing on microdosing psychedelic medicines provide hope for sufferers of mental health conditions. The Australian company has conducted a randomized, double-blind, placebo-controlled trial to study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males. MindBio Therapeutics was founded by Justin Adam Hanka, and the CEO is Colin Keating.